List of Related Excipient Companies and Suppliers of DSSTox_CID_3746 by Dfe Pharma on PharmaCompass.com

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

FDF DossiersDRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Annual Reports

NA

171 RELATED EXCIPIENT COMPANIES

284EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 107753-78-6, Accolate, Olmoran, Ici-204219, Cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1h-indol-5-yl)carbamate, Accoleit
Molecular Formula
C31H33N3O6S
Molecular Weight
575.7  g/mol
InChI Key
YEEZWCHGZNKEEK-UHFFFAOYSA-N
FDA UNII
XZ629S5L50

Zafirlukast
Zafirlukast is a tolyl compound and leukotriene receptor antagonist (LTRA), with anti-asthmatic and potential capsular contracture-preventing activities. Upon administration, zafirlukast selectively and competitively binds to and blocks the cysteinyl leukotriene 1 receptor (CYSLTR1), thereby preventing the potent pro-inflammatory mediators leukotriene C4, D4 and E4 from binding. This prevents leukotriene-mediated actions, including enhanced migration of eosinophils and neutrophils, increased adhesion of leukocytes, increased monocyte and neutrophil aggregation, increased airway edema, inflammation, capillary permeability and bronchoconstriction. In addition, zafirlukast may decrease collagen deposition, fibrosis, and capsular thickness after implantation, thereby preventing scar tissue.
Zafirlukast is a Leukotriene Receptor Antagonist. The mechanism of action of zafirlukast is as a Leukotriene Receptor Antagonist, and Cytochrome P450 2C9 Inhibitor.
1 2D Structure

Zafirlukast

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate
2.1.2 InChI
InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)
2.1.3 InChI Key
YEEZWCHGZNKEEK-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC
2.2 Other Identifiers
2.2.1 UNII
XZ629S5L50
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 4-(5-cyclopentyloxycarbonylamino-2-methylindol-3-yl-methyl)-3-methoxy-n-o-tolylsulfonylbenzamide

2. Accolate

3. Aeronix

4. Ici 204,219

5. Ici 204219

6. Ici-204219

7. Olmoran

2.3.2 Depositor-Supplied Synonyms

1. 107753-78-6

2. Accolate

3. Olmoran

4. Ici-204219

5. Cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1h-indol-5-yl)carbamate

6. Accoleit

7. Vanticon

8. Ici 204219

9. Ici 204,219

10. Cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate

11. Zafirlukast (accolate)

12. Chembl603

13. Aeronix

14. Chebi:10100

15. Xz629s5l50

16. 4-(5-cyclopentyloxycarbonylamino-1-methyl-1h-indol-3-ylmethyl)-3-methoxy-n-o-tolylsulfonylbenzamide

17. Ici-204,219

18. Ncgc00164547-01

19. Ncgc00164547-06

20. Dsstox_cid_3746

21. Dsstox_rid_77181

22. Dsstox_gsid_23746

23. Cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1h-indol-5-ylcarbamate

24. Cyclopentyl N-[3-[[2-methoxy-4-(o-tolylsulfonylcarbamoyl)phenyl]methyl]-1-methyl-indol-5-yl]carbamate

25. Zafirst

26. Respix

27. C31h33n3o6s

28. Accolate (tn)

29. Cyclopentyl 3-{2-methoxy-4-[(o-tolylsulfonyl)carbamoyl]benzyl}-1-methyl-1h-indol-5-ylcarbamate

30. Cyclopentyl N-{3-[(2-methoxy-4-{[(2-methylbenzene)sulfonyl]carbamoyl}phenyl)methyl]-1-methyl-1h-indol-5-yl}carbamate

31. Smr000466316

32. Cas-107753-78-6

33. Sr-01000759386

34. Zafirlucast

35. Unii-xz629s5l50

36. Zafirlukast (jan/usan/inn)

37. Zafirlukast [usan:inn:ban]

38. Zafirlukast- Bio-x

39. Mfcd00864775

40. Zafirlukast(accolate)

41. Cpd000466316

42. Zafirlukast [mi]

43. Zafirlukast [inn]

44. Zafirlukast [jan]

45. Zafirlukast [usan]

46. Zafirlukast [vandf]

47. Schembl4175

48. Zafirlukast [mart.]

49. Zafirlukast [who-dd]

50. Carbamic Acid, (3-((2-methoxy-4-((((2-methylphenyl)sulfonyl)amino)carbonyl)phenyl)methyl)-1-methyl-1h-indol-5-yl)-, Cyclopentyl Ester

51. Cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate

52. Mls000759421

53. Mls001424064

54. Mls006011771

55. Bidd:gt0267

56. Gtpl3322

57. Dtxsid5023746

58. Zafirlukast, >=98% (hplc)

59. Zafirlukast [orange Book]

60. Hms2051f12

61. Hms2089j10

62. Hms3393f12

63. Hms3650a04

64. Hms3655e13

65. Hms3713j08

66. Hms3745k03

67. Zinc896717

68. Bcp05226

69. Tox21_112176

70. Bdbm50009073

71. S1633

72. Stk646780

73. Akos005577888

74. Tox21_112176_1

75. Ac-9018

76. Ccg-101025

77. Db00549

78. Nc00275

79. Sb19079

80. Ncgc00164547-02

81. Ncgc00164547-03

82. Ncgc00164547-04

83. Ncgc00164547-05

84. As-12943

85. Bz164562

86. Cyclopentyl (1-methyl-3-{[2-(methyloxy)-4-({[(2-methylphenyl)sulfonyl]amino}carbonyl)phenyl]methyl}-1h-indol-5-yl)carbamate

87. Cyclopentyl [3-(2-methoxy-4-{[(2-methylphenyl)sulfonyl]carbamoyl}benzyl)-1-methyl-1h-indol-5-yl]carbamate

88. Hy-17492

89. N-[3-[[2-methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1h-indol-5-yl]carbamic Acid Cyclopentyl Ester

90. Ft-0601575

91. Mls000759421-02

92. Sw197655-3

93. Z0029

94. C07206

95. D00411

96. D92802

97. Ab00639922-06

98. Ab00639922-08

99. Ab00639922_09

100. 753z786

101. A801752

102. L001011

103. Q928378

104. Q-201940

105. Sr-01000759386-4

106. Sr-01000759386-5

107. Sr-01000759386-9

108. Brd-k71289571-001-06-4

109. Z1551429730

110. Carbamic Acid, (3-((2-methoxy-4-(((2-methylphenyl)sulfonyl)amino)carbonyl)phenyl)methyl)-1-methyl-1h-indol-5-yl)-, Cyclopentyl Ester

111. Carbamic Acid, N-[3-[[2-methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1h-indol-5-yl]-, Cyclopentyl Ester

112. Cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)-carbamoyl)benzyl)-1-methyl-1h-indol-5-yl)carbamate

113. Cyclopentyl 3-(2-methoxy-4-(o-tolylsulfonylcarbamoyl)benzyl)-1-methyl-1h-indol-5-ylcarbamate

114. Cyclopentyl N-[3-({2-methoxy-4-[(2-methylbenzenesulfonyl)carbamoyl]phenyl}methyl)-1-methyl-1h-indol-5-yl]carbamate

115. Cyclopentyl N-[3-[[2-methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1h-indol-5-yl]carbamate

116. Zlk

2.4 Create Date
2004-09-16
3 Chemical and Physical Properties
Molecular Weight 575.7 g/mol
Molecular Formula C31H33N3O6S
XLogP35.5
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count6
Rotatable Bond Count9
Exact Mass575.20900695 g/mol
Monoisotopic Mass575.20900695 g/mol
Topological Polar Surface Area124 Ų
Heavy Atom Count41
Formal Charge0
Complexity1010
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 4  
Drug NameAccolate
PubMed HealthZafirlukast (By mouth)
Drug ClassesAnti-Inflammatory
Drug LabelZafirlukast is a synthetic, selective peptide leukotriene receptor antagonist (LTRA), with the chemical name 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide. The molecular weight of zafirlukast is 575...
Active IngredientZafirlukast
Dosage FormTablet
RouteOral
Strength10mg; 20mg
Market StatusPrescription
CompanyAstrazeneca

2 of 4  
Drug NameZafirlukast
PubMed HealthZafirlukast (By mouth)
Drug ClassesAnti-Inflammatory
Drug LabelZafirlukast is a synthetic, selective peptide leukotriene receptor antagonist (LTRA), with the chemical name 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide. The molecular weight of zafirlukast is 575...
Active IngredientZafirlukast
Dosage FormTablet
RouteOral
Strength10mg; 20mg
Market StatusPrescription
CompanyDr Reddys Labs

3 of 4  
Drug NameAccolate
PubMed HealthZafirlukast (By mouth)
Drug ClassesAnti-Inflammatory
Drug LabelZafirlukast is a synthetic, selective peptide leukotriene receptor antagonist (LTRA), with the chemical name 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide. The molecular weight of zafirlukast is 575...
Active IngredientZafirlukast
Dosage FormTablet
RouteOral
Strength10mg; 20mg
Market StatusPrescription
CompanyAstrazeneca

4 of 4  
Drug NameZafirlukast
PubMed HealthZafirlukast (By mouth)
Drug ClassesAnti-Inflammatory
Drug LabelZafirlukast is a synthetic, selective peptide leukotriene receptor antagonist (LTRA), with the chemical name 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide. The molecular weight of zafirlukast is 575...
Active IngredientZafirlukast
Dosage FormTablet
RouteOral
Strength10mg; 20mg
Market StatusPrescription
CompanyDr Reddys Labs

4.2 Drug Indication

For the prophylaxis and chronic treatment of asthma.


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

Zafirlukast is a synthetic, selective peptide leukotriene receptor antagonist (LTRA) indicated for the prophylaxis and chronic treatment of asthma. Patients with asthma were found in one study to be 25-100 times more sensitive to the bronchoconstricting activity of inhaled LTD4 than nonasthmatic subjects. In vitro studies demonstrated that zafirlukast antagonized the contractile activity of three leukotrienes (LTC4, LTD4 and LTE4) in conducting airway smooth muscle from laboratory animals and humans. Zafirlukast prevented intradermal LTD4-induced increases in cutaneous vascular permeability and inhibited inhaled LTD4-induced influx of eosinophils into animal lungs.


5.2 MeSH Pharmacological Classification

Anti-Asthmatic Agents

Drugs that are used to treat asthma. (See all compounds classified as Anti-Asthmatic Agents.)


Leukotriene Antagonists

A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level. (See all compounds classified as Leukotriene Antagonists.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
ZAFIRLUKAST
5.3.2 FDA UNII
XZ629S5L50
5.3.3 Pharmacological Classes
Leukotriene Receptor Antagonist [EPC]; Leukotriene Receptor Antagonists [MoA]; Cytochrome P450 2C9 Inhibitors [MoA]
5.4 ATC Code

R - Respiratory system

R03 - Drugs for obstructive airway diseases

R03D - Other systemic drugs for obstructive airway diseases

R03DC - Leukotriene receptor antagonists

R03DC01 - Zafirlukast


5.5 Absorption, Distribution and Excretion

Absorption

Rapidly absorbed following oral administration, reduced following a high-fat or high-protein meal.


Route of Elimination

The most common metabolic products are hydroxylated metabolites which are excreted in the feces.


Volume of Distribution

70 L


Clearance

apparent oral CL=20 L/h

11.4 L/h [7-11 yrs]

9.2 L/h [5-6 yrs]


5.6 Metabolism/Metabolites

Hepatic


Zafirlukast has known human metabolites that include 3-hydroxycyclopentyl N-[3-({2-methoxy-4-[(2-methylbenzenesulfonyl)carbamoyl]phenyl}methyl)-1-methylindol-5-yl]carbamate and cyclopentyl N-[1-(hydroxymethyl)-3-({2-methoxy-4-[(2-methylbenzenesulfonyl)carbamoyl]phenyl}methyl)indol-5-yl]carbamate.

S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560


5.7 Biological Half-Life

10 hours


5.8 Mechanism of Action

Zafirlukast is a selective and competitive receptor antagonist of leukotriene D4 and E4 (LTD4 and LTE4), components of slow-reacting substance of anaphylaxis (SRSA). Cysteinyl leukotriene production and receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle constriction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma.


API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1717353000,"product":"ZAFIRLUKAST BATCH NO-QC-ZAF-PRS-04-02","address":"OLD NO.1\/63, NEW NO.1\/58,PUDUPAKKAM","city":"ROAD, KELAMBAKKAM \/CHENNAI\/ TAMILNA","supplier":"PAR ACTIVE TECHNOLOGIES ","supplierCountry":"INDIA","foreign_port":"NEW YORK","customer":"STRIDES PHARMA SCIENCE","customerCountry":"UNITED STATES","quantity":"0.01","actualQuantity":"0.005","unit":"KGS","unitRateFc":"250000","totalValueFC":"1243.7","currency":"USD","unitRateINR":20656248,"date":"03-Jun-2024","totalValueINR":"103281.24","totalValueInUsd":"1243.7","indian_port":"Madras Air","hs_no":"29359090","bill_no":"1394439","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Madras Air","supplierAddress":"OLD NO.1\/63, NEW NO.1\/58,PUDUPAKKAM, ROAD, KELAMBAKKAM \/CHENNAI\/ TAMILNA","customerAddress":""}]
03-Jun-2024
03-Jun-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - TABLET;ORAL - 10MG

USFDA APPLICATION NUMBER - 20547

read-more

DOSAGE - TABLET;ORAL - 20MG

USFDA APPLICATION NUMBER - 20547

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Coating Systems & Additives

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Direct Compression

read-more
read-more

Controlled & Modified Release

read-more
read-more

Granulation

read-more
read-more

Co-Processed Excipients

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Lubricants & Glidants

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Solubilizers

read-more
read-more

Empty Capsules

read-more
read-more

Parenteral

read-more
read-more

Vegetarian Capsules

read-more
read-more

Taste Masking

read-more
read-more

Coloring Agents

read-more
read-more

Rheology Modifiers

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

API Stability Enhancers

read-more
read-more

Emulsifying Agents

read-more
read-more

Topical

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty